Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled “Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes.” It is in the 15 August 2000 issue of Annals of Internal Medicine (volume 133, pages 263-274). The authors are E. Arioglu, J. Duncan-Morin, N. Sebring, K.I. Rother, N. Gottlieb, J. Lieberman, D. Herion, D.E. Kleiner, J. Reynolds, A. Premkumar, A.E. Sumner, J. Hoofnagle, M.L. Reitman, and S.I. Taylor.
Using Troglitazone To Treat People with Lipoatrophy Syndromes. Ann Intern Med. 2000;133:263. doi: https://doi.org/10.7326/0003-4819-133-4-200008150-00037
Download citation file:
Published: Ann Intern Med. 2000;133(4):263.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Obesity.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use